Identification of Specific Modulation Frequencies in Hepatitis B Carriers With and Without Hepatocellular Carcinoma

Status

Completed

Phases

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT01641276

Acronym

THBC-HSL2

Enrollment

Registered

2012-07-16

Start date

2012-04-30

Completion date

2015-06-30

Last updated

2015-09-14

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Hepatitis, Hepatocellular Carcinomas

Keywords

biofeedback response

Brief summary

The propose of this study is to identification of a group of specific amplitude-modulated frequencies of low intensity electromagnetic fields that is associated with biofeedback upon exposure to in patients with hepatitis B carries with or without hepatocellular carcinoma.

Detailed description

Patients will be exposed by different specific amplitude-modulated frequencies of low intensity electromagnetic fields for 30 min. During the exposure, autonomic response with be recorded in order to identify biofeedback response. Differences in group of frequencies is expected in patients with hepatitis B carries with or without hepatocellular carcinoma.

Interventions

DEVICELow intensity amplitude-moduled electromagnetic fields

Patients in each arm will be exposed to 30 min of amplitude-moduled low intensity electromagnetic fields only one time.

Study design

Allocation

RANDOMIZED

Intervention model

PARALLEL

Primary purpose

DIAGNOSTIC

Masking

DOUBLE (Subject, Investigator)

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

Yes

Inclusion criteria

* hepatitis B carriers patients * hepatitis B carriers patients with hepatocellular cancer patients

Exclusion criteria

* other tumor types * other hepatitis types

Design outcomes

Primary

Measure	Time frame	Description
Identification of different group of specific frequencies of modulation in hepatitis B carriers with and without hepatocellular carcinoma associated with biofeedback response	within 10 min of exposure	biofeedback response will be monitored

Secondary

Measure	Time frame	Description
Characterization of differences biofeedback response in hepatitis B carriers with and without hepatocellular carcinoma	within 10 minutes of exposure	Representation of autonomous response during the exposure of specific frequencies of modulation

Countries

Brazil

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026